(Amsterdam, March 16th 2016) Genetic Analysis AS has reported preliminary results in the pan European study “IBD Character” at the European Crohn’s and Colitis Organization’s (ECCO) Annual congress. Using the proprietary GA-map™ Dysbiosis Test, fecal microbiota dysbiosis patterns revealed that IBD and its subgroups are dominated by differing bacteria profiles.
The main task for Genetic Analysis (GA) as a partner in the IBD character project was to develop a novel diagnostic test for determining microbial dysbiosis. The development has been accomplished, and the test is now available as the CE-marked GA-map ™ Dysbiosis Test.
Preliminary results were presented at ECCO2016 and comprised results from several cohorts; treatment naive IBD, non-IBD patients and healthy controls. In total 292 subjects were included in the data analysis. As expected, the Dysbiosis (deviating bacteria composition) in the healthy controls showed mostly non- to mild dysbiosis. The non-IBD and IBD patients were more represented in the severe dysbiosis range.
Bacteria profiles in IBD
Additionally, Escherichia (Proteobacteria) were significantly increased (P<0,02) in the non-IBD and the IBD cohort as compared to controls. Clear gradual reductions in bacterial abundance were identified from the healthy controls through non-IBD to IBD patients in the species Faecalibacterium prausnitzii (P<0,07) and the Bifidobacteria genus (P<0,02). Differences in bacteria profiles between Ulcerative colitis (UC) and Crohn’s disease (CD) were also observed. Firmicutes, Streptococcus and Clostridia were significantly reduced in UC as compared to CD patients.
Subgroups of UC patients
Surprisingly, when looking at the subgroups of the UC cohorts, cluster analysis showed that control samples and UC proctitis cluster separately from leftsided/pancolitis (more advanced disease), indicating that the microbiota profiles are dominated by different bacteria. Especially, these deviations were driven by a decrease in Bifidobacterium and an increase in Escherichia in the patients with leftsided/pancolitis.
ECCO 2016 – a shift from microbiota profiling to response prediction
ECCO’s focus is Inflammatory Bowel Disease (IBD) and is a meeting with high scientific standard for gastroenterologists discussing new trends in diagnostics, treatment, and disease development. “At ECCO this year, the focus has shifted from mere microbial profiling – to discussing specific ways to target dysbiosis and using microbiota profiles to predict response of treatments.” said gastroenterologist MD PhD Petr Ricanek, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
About Genetic Analysis
Genetic Analysis has developed and launched the first gene-based routine test for the mapping and diagnosis of diseases related to dysbiosis and imbalances in the bacteria in the digestive system. The company markets the GA-map™ technology to three market segments: commercial routine testing, pharma companies and the research market. Genetic Analysis was established in 2008 and is based on research done by Professor Knut Rudi at Norwegian University of Life Sciences, NMBU and Nofima Mat in Ås. www.genetic-analysis.com
Comments are closed.